Bemcentinib – A selective AXL inhibitor currently in Phase II
Learn MoreLATEST EVENT
BERGENBIO TO PRESENT AT ABGSC SEMINAR
Date: 21st May 2021 Time: 10:30 am
BerGenBio CEO Richard Godfrey comments on a very exciting and encouraging week for BerGenBio
(11 June 2021) BerGenBio’s CEO, Richard Godfrey, provides an update after a very encouraging week for the company, with the FDA granting fast track designation for a combination bemcentinib treatment in NSCLC, AML research updates presented at EHA and a late-breaking abstract accepted at ECCMID.
Scientific Presentations
EHA 2021, Dr. Sonja Loges et al.
11 June 2021
The combination of AXL inhibitor bemcentinib and low-dose cytarabine is well tolerated and efficacious in elderly relapsed AML patients: Update from the ongoing BGBC003 Phase II trial (NCT02488408)
Pipeline of first-in-class AXL inhibitors for the treatment of aggressive diseases.
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection.
BerGenBio’s lead candidate, bemcentinib, is a once-a-day, oral, highly selective and potent inhibitor of AXL kinase, which has demonstrated a key role in cancer treatment by preventing immune evasion, drug resistance and metastasis in a variety of cancer trials.
Additionally, bemcentinib has been reported to exhibit potent anti-viral activity in preclinical models of infection by enveloped viruses, including Ebola and Zika. Recent data have expanded this to SARS-CoV-2 where findings suggest that bemcentinib stops the virus entering the host cells and neutralising its anti-viral defence mechanisms. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (OSE:BGBIO).
Explore BerGenBio’s pipelineLatest News
BERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN RELAPSED AML PATIENTS AT EHA VIRTUAL MEETING
Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients Bergen, Norway, 11 June 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical
Read moreBERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021
Bergen, Norway, 10 June 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stagebiopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces that an analysis
Read moreBERGENBIO RECEIVED FDA FAST-TRACK DESIGNATION FOR BEMCENTINIB / ANTI-PD-(L)1 COMBINATION IN NSCLC
First recognition by a regulator of AXL-positive patients as a target population Bergen, Norway, 08 June 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective
Read moreBERGENBIO TO PRESENT PRECLINICAL DATA ON TILVESTAMAB IN CHRONIC KIDNEY DISEASE AT ERA-EDTA VIRTUAL CONGRESS 2021
Bergen, Norway, 07 June 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to present preclinical
Read more
